www.arcalyst.com Open in urlscan Pro
54.243.156.10  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main content


HCP UTILITY NAVIGATION

 * Coverage Finder
 * Enrollment Form
   * Recurrent Pericarditis (English)
   * Recurrent Pericarditis (Spanish)
   * CAPS/DIRA
 * Enrollment Form
   * English
 * Prescribing Information
   * English
 * Sign Up
 * For Patients

Arcalyst


HCP DROPDOWN NAVIGATION

Select Condition:
 * Recurrent Pericarditis
   * CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
   * DEFICIENCY OF INTERLEUKIN (IL-1) RECEPTOR ANTAGONIST (DIRA)


HCP MAIN NAVIGATION

 * Why ARCALYST?
 * Breakthrough Results
 * Safety and Administration
 * Access and Support
 * Coverage Finder
 * Sign Up
 * Enrollment Form
 * Prescribing Information
   * English

Menu

View results from the 24-month RHAPSODY long-term extension
Scroll or click


FINALLY, A BREAKTHROUGH TREATMENT


FOR YOUR PATIENTS WITH RECURRENT PERICARDITIS1


FINALLY, A BREAKTHROUGH TREATMENT


FOR YOUR PATIENTS WITH RECURRENT PERICARDITIS1






ARCALYST® (RILONACEPT) IS THE FIRST AND ONLY FDA-APPROVED TREATMENT INDICATED
FOR THE TREATMENT OF RECURRENT PERICARDITIS AND THE REDUCTION IN RISK OF
RECURRENCE IN ADULTS AND CHILDREN 12 YEARS AND OLDER1.

ARCALYST, an IL-1 soluble decoy receptor, blocks the underlying mechanism that
drives inflammation in recurrent pericarditis.


ARCALYST AT A GLANCE



THE RISK OF RECURRENCE

Up to
30%
of individuals with a first episode of acute pericarditis will experience a
recurrence totaling ~40,000 patients.2,3

Learn more about the prevalence of recurrent pericarditis, the underlying cause
of recurrent inflammation, and why reducing the risk of recurrence matters for
your patients.

Why ARCALYST?

BREAKTHROUGH RESULTS

In the pivotal trial,
96%
reduction in risk of recurrent pericarditis episodes
(hazard ratio: 0.04; p<0.0001).1



The efficacy and safety of ARCALYST were evaluated in RHAPSODY, a Phase 3,
double-blind, placebo-controlled, event-driven, randomized withdrawal study
(N=61).

The primary efficacy endpoint was time to first adjudicated pericarditis
recurrence in the randomized withdrawal period.

Clinical results

ONCE-WEEKLY TREATMENT

1x
Once-weekly subcutaneous injection.1

Get familiar with the safety profile, dosing and administration, and treatment
duration of ARCALYST.

Safety, administration, and treatment duration



ACCESS AND RESOURCES

 

The Kiniksa OneConnect program was created to help make treatment support simple
for healthcare providers and patients.

Start your patient on ARCALYST
Request to speak to a
Clinical Sales Specialist
Expand
Important Safety Information

Warnings and Precautions

 * Interleukin-1 (IL-1) blockade may interfere with the immune response to
   infections. Treatment with another medication that works through inhibition
   of IL-1 or inhibition of tumor necrosis factor (TNF) is not recommended as
   this may increase the risk of serious infection. Serious, life-threatening
   infections have been reported in patients taking ARCALYST. Do not initiate
   treatment with ARCALYST in patients with an active or chronic infection.
 * Discontinue ARCALYST if a patient develops a serious infection.
 * It is possible that taking drugs such as ARCALYST that block IL-1 may
   increase the risk of tuberculosis (TB) or other atypical or opportunistic
   infections.
 * Although the impact of ARCALYST on infections and the development of
   malignancies is not known, treatment with immunosuppressants, including
   ARCALYST, may result in an increase in the risk of malignancies.
 * Hypersensitivity reactions associated with ARCALYST occurred in clinical
   trials. Discontinue ARCALYST and initiate appropriate therapy if a
   hypersensitivity reaction occurs. 
 * Increases in non-fasting lipid profile parameters occurred in patients
   treated with ARCALYST in clinical trials. Patients should be monitored for
   changes in their lipid profiles.
 * Since no data are available, avoid administration of live vaccines while
   patients are receiving ARCALYST. ARCALYST may interfere with the normal
   immune response to new antigens, so vaccines may not be effective in patients
   receiving ARCALYST. It is recommended that, prior to initiation of therapy
   with ARCALYST, patients receive all recommended vaccinations, as appropriate.

Adverse Reactions

 * In patients with CAPS or RP, the most common adverse reactions (≥10%) include
   injection-site reactions and upper respiratory tract infections.
 * In patients with DIRA, the most common adverse reactions (>10%) include upper
   respiratory tract infections, rash, otitis media, pharyngitis, and
   rhinorrhea.

Drug Interactions

 * In patients being treated with CYP450 substrates with narrow therapeutic
   indices, therapeutic monitoring of the effect or drug concentration should be
   performed, and the individual dose of the medicinal product may need to be
   adjusted.

For more information about ARCALYST, see full Prescribing Information.

Indication

ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for:

 * Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence
   in adults and pediatric patients 12 years and older.
 * Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including
   Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome
   (MWS) in adults and children 12 years and older. 
 * Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist
   (DIRA) in adults and pediatric patients weighing 10 kg or more.

 

References

 1. ARCALYST. Package insert. Kiniksa Pharmaceuticals (UK), Ltd.; 2021. 2.
Cremer PC, Kumar A, Kontzias A, et al. Complicated pericarditis: understanding
risk factors and pathophysiology to inform imaging and treatment. J Am Coll
Cardiol. 2016;68(21):2311-2328. 3. Data on file #1. Kiniksa Pharmaceuticals
(UK), Ltd.

 


HCP FOOTER QUICK LINKS

 * Why ARCALYST?
 * Breakthrough Results
 * Safety and Administration
 * Access and Support

 


HCP FOOTER NAVIGATION

 * Terms of Use
 * Privacy Policy
 * Contact Us

This site is intended for US audiences only. 
ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. 
Kiniksa OneConnect is a trademark of Kiniksa Pharmaceuticals. 
© 2024 Kiniksa Pharmaceuticals (UK), Ltd. All Rights Reserved. 01/24
ARC-US-00482-23

Go Back Continue
×





PRIVACY PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
More information
Allow All


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.
These cookies do not store any personally identifiable information.

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.

FUNCTIONAL COOKIES

Functional Cookies

These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages. If you do not allow these cookies then some
or all of these services may not function properly.

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.


BACK BUTTON PERFORMANCE COOKIES



Vendor Search Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Confirm My Choices


By clicking “Accept All Cookies”, you agree to the storing of cookies on your
device to enhance site navigation, analyze site usage, and assist in our
marketing efforts.

Cookies Settings Accept All Cookies